@article{caec3f71b830498b82eceaf9f84c5936,
title = "Uveal melanoma, version 1.2019 featured updates to the NCCN guidelines",
abstract = "The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body. In addition, because distinguishing between uveal melanoma and benign uveal nevi is in some cases difficult, these guidelines also contain recommendations for workup of patients with suspicious pigmented uveal lesions, to clarify the tests needed to distinguish between those who should have further workup and treatment for uveal melanoma versus those with uncertain diagnosis and low risk who should to be followed and later reevaluated. These NCCN Guidelines Insights describe recommendations for treatment of newly diagnosed nonmetastatic uveal melanoma in patients who have already undergone a complete workup.",
author = "{Kumar Rao}, P. and Christopher Barker and Coit, {Daniel G.} and Joseph, {Richard W.} and Miguel Materin and Ramesh Rengan and Jeffrey Sosman and Thompson, {John A.} and Albertini, {Mark R.} and Genevieve Boland and Carson, {William E.} and Carlo Contreras and Daniels, {Gregory A.} and Dominick DiMaio and Alison Durham and Fields, {Ryan C.} and Fleming, {Martin D.} and Anjela Galan and Brian Gastman and Kenneth Grossman and Valerie Guild and Douglas Johnson and Giorgos Karakousis and Lange, {Julie R.} and Kim Margolin and Sameer Nath and Olszanski, {Anthony J.} and Ott, {Patrick A.} and Ross, {Merrick I.} and Salama, {April K.} and Joseph Skitzki and Swetter, {Susan M.} and Evan Wuthrick and McMillian, {Nicole R.} and Anita Engh",
note = "Funding Information: This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Coherus BioSciences; Genentech, a member of the Roche Group; and TESARO, a GSK Company. This activity is supported in part by an educational grant from Bayer Healthcare Pharmaceuticals. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc. Publisher Copyright: {\textcopyright} 2020 Harborside Press. All rights reserved.",
year = "2020",
doi = "10.6004/jnccn.2020.0006",
language = "English",
volume = "18",
pages = "121--131",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
number = "2",
}